Prof Fran Balkwill
Deputy Lead, Centre for Tumour Microenvironment
Barts Cancer Institute
Queen Mary University of London
Queen Mary University of London
Research
cancer, tumour microenvironment, multi-cellular models, ovarian cancer, extracellular matrix, immunotherapy
Interests
The interest and experience of my laboratory relates to complex multi-cellular models MCMs of the tumour microenvironment, especially in ovarian cancer. Having completed a multi-level deconstruction of ovarian cancer metastases, we have begun to reconstruct 3D multi-cellular models of these metastases using primary adipocytes, fibroblasts, mesothelial cells, monocytes and malignant cells. We are also currently working to vascularise these MCMs. We are using the models to understand cell cell communication in the tumour microenvironment, test new biological therapies and study sensitivity and resistance to T cell killing.Publications
Publications of specific relevance to Predictive <em>in vitro</em> Models2024
Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancerElorbany S, Berlato C, Carnevalli LS, Maniati E, Barry ST, Wang J, Manchanda R, Kzhyshkowska J and Balkwill F
Nature Communications, Springer Nature vol. 15 (1)
22-11-2024
Human 3D Ovarian Cancer Models Reveal Malignant Cell-Intrinsic and -Extrinsic Factors That Influence CAR T-cell Activity.Joy JD, Malacrida B, Laforêts F, Kotantaki P, Maniati E, Manchanda R, Annibaldi A, Hopkins S, Garrobo-Calleja I, Gautrot J and Balkwill FR
Cancer Res vol. 84 (15), 2432-2449.
01-08-2024
Protocol for real-time monitoring of CD8+ T and myeloid cell behavior in human high-grade serous ovarian cancer slicesLaforêts F, Donnadieu E and Balkwill F
Star Protocols, Elsevier vol. 5 (2)
01-06-2024
P33 Skinvaders: gamification of the skin barrier to engage school-age children in the biology of the skinde Brito M, Green F, McCarthy R, Rees M, Balkwill F and O’Toole EA
British Journal of Dermatology, Oxford University Press (Oup) vol. 190 (6), e94-e95.
17-05-2024
Correction: Developmental Trajectories of Adolescents’ Math Motivation: The Role of Mindset and Perceptions of Informal STEM Learning Site InclusivityOzturk E, Zhao M, Hoffman AJ, Joy A, Marlow CS, Law F, Deutsch AR, Mathews CJ, McGuire L, Balkwill F, Burns K, Butler L, Drews M, Fields G, Smith H, Winterbottom M, Rutland A, Hartstone-Rose A and Mulvey KL
Journal of Youth and Adolescence, Springer Nature vol. 53 (8), 1940-1940.
10-04-2024
The relations between growth mindset, motivational beliefs, and career interest in math intensive fields in informal STEM youth programsOzturk E, Zhao M, Joy A, Marlow CS, Law F, Deutsch AR, Mathews CJ, Hoffman AJ, McGuire L, Winterbottom M, Balkwill F, Burns K, Butler L, Drews M, Fields G, Smith H, Rutland A, Hartstone-Rose A and Mulvey KL
Plos One, Public Library of Science (Plos) vol. 19 (4)
09-04-2024
Developmental Trajectories of Adolescents’ Math Motivation: The Role of Mindset and Perceptions of Informal STEM Learning Site InclusivityOzturk E, Zhao M, Hoffman AJ, Joy A, Marlow CS, Law F, Deutsch AR, Mathews CJ, McGuire L, Balkwill F, Burns K, Butler L, Drews M, Fields G, Smith H, Winterbottom M, Rutland A, Hartstone-Rose A and Mulvey KL
Journal of Youth and Adolescence, Springer Nature vol. 53 (7), 1542-1563.
28-02-2024
2023
Investigating the impact of London’s ultra low emission zone on children’s health: children’s health in London and Luton (CHILL) protocol for a prospective parallel cohort studyTsocheva I, Scales J, Dove R, Chavda J, Kalsi H, Wood HE, Colligan G, Cross L, Newby C, Hall A, Keating M, Sartori L, Moon J, Thomson A, Tomini F, Murray A, Hamad W, Tijm S, Hirst A, Vincent BP, Kotala P, Balkwill F, Mihaylova B, Grigg J, Quint JK, Fletcher M, Mon-Williams M, Wright J, van Sluijs E and Beevers S
Bmc Pediatrics, Springer Nature vol. 23 (1)
04-11-2023
CD73 controls Myosin II–driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cellsSamain R, Maiques O, Monger J, Lam H, Candido J, George S, Ferrari N, KohIhammer L, Lunetto S, Varela A, Orgaz JL, Vilardell F, Olsina JJ, Matias-Guiu X, Sarker D, Biddle A, Balkwill FR, Eyles J, Wilkinson RW, Kocher HM, Calvo F, Wells CM and Sanz-Moreno V
Science Advances, American Association For The Advancement of Science (Aaas) vol. 9 (42)
18-10-2023
Reciprocal Associations Between Science Efficacy, STEM Identity and Scientist Career Interest Among Adolescent Girls within the Context of Informal Science LearningZhao M, Ozturk E, Law F, Joy A, Deutsch AR, Marlow CS, Mathews CJ, McGuire L, Hoffman AJ, Balkwill F, Burns KP, Butler L, Drews M, Fields G, Smith H, Winterbottom M, Mulvey KL, Hartstone-Rose A and Rutland A
Journal of Youth and Adolescence, Springer Nature vol. 53 (2), 472-484.
11-10-2023
Interferon epsilon and ovarian cancerElorbany S, Malacrida B and Balkwill F
Trends in Cancer, Elsevier vol. 9 (12), 985-986.
29-09-2023
Children's and adolescents’ evaluations of wealth‐related STEM inequalityMcGuire L, Marlow C, Hoffman AJ, Joy A, Law F, Hartstone‐Rose A, Rutland A, Winterbottom M, Balkwill F, Burns KP, Butler L, Fields G and Mulvey KL
Social Development, Wiley vol. 33 (1)
22-09-2023
Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesotheliomaPhillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C, Feng S, Hallden G, Chelala C, Bomalaski J, Steele J, Sheaff M, Balkwill F and Szlosarek PW
Pharmacological Reports, Springer Nature vol. 75 (3), 753-753.
17-05-2023
Device-Measured Change in Physical Activity in Primary School Children During the UK COVID-19 Pandemic Lockdown: A Longitudinal StudyScales J, Chavda J, Ikeda E, Tsocheva I, Dove RE, Wood HE, Kalsi H, Colligan G, Griffiths L, Day B, Crichlow C, Keighley A, Fletcher M, Newby C, Tomini F, Balkwill F, Mihaylova B, Grigg J, Beevers S, Eldridge S, Sheikh A, Gauderman J, Kelly F, Randhawa G, Mudway IS, van Sluijs E and Griffiths CJ
Journal of Physical Activity and Health, Human Kinetics vol. 20 (7), 639-647.
04-05-2023
Abstract LB195: Immunotherapies that repolarize macrophages and CD4 T cells enhance the effect of chemotherapy in high-grade serous ovarian cancerElorbany S, Berlato C, Carnevalli L, Maniati E, Wang J, Barry S, Manchanda R, Kzhyshkowska J and Balkwill F
Cancer Research, American Association For Cancer Research (Aacr) vol. 83 (8_Supplement), lb195-lb195.
14-04-2023
The impact of pericytes on the stability of microvascular networks in response to nanoparticlesDibble M, Di Cio’ S, Luo P, Balkwill F and Gautrot JE
Scientific Reports, Springer Nature vol. 13 (1)
07-04-2023
Abstract 5957: Chemotherapy-induced extracellular matrix remodeling in HGSOCKotantaki P, Laforêts F, Maniati E, Berlato C, Malliouri A, Devlin MJ, Malacrida B, Elorbany S, Manchanda R and Balkwill FR
Cancer Research, American Association For Cancer Research (Aacr) vol. 83 (7_Supplement), 5957-5957.
04-04-2023
Abstract 5913: Semi-supervised analysis of myeloid and T cell behavior in ex vivo ovarian tumor slices reveals changes in cell motility after treatmentsLaforets F, Kotantaki P, Malacrida B, Elorbany S, Manchanda R, Donnadieu E and Balkwill F
Cancer Research, American Association For Cancer Research (Aacr) vol. 83 (7_Supplement), 5913-5913.
04-04-2023
Abstract 4576: 3D in vitro models uncover malignant cell intrinsic and extrinsic mechanisms of CAR-T cell resistance in high grade serous ovarian cancerJoy JD, Malacrida B, Laforêts F, Kotantaki P, Maniati E, Hopkins S, Garrobo-Calleja I, Gautrot J and Balkwill F
Cancer Research, American Association For Cancer Research (Aacr) vol. 83 (7_Supplement), 4576-4576.
04-04-2023
Abstract 4551: Reconstructing the metastatic tumor microenvironment of high grade serous ovarian cancer: understanding the contribution of malignant cellsMalacrida B, Elorbany S, Maniati E, Laforets F, Manchanda R and Balkwill FR
Cancer Research, American Association For Cancer Research (Aacr) vol. 83 (7_Supplement), 4551-4551.
04-04-2023
A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesotheliomaPhillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C, Feng S, Hallden G, Chelala C, Bomalaski J, Steele J, Sheaff M, Balkwill F and Szlosarek PW
Pharmacological Reports, Springer Nature vol. 75 (3), 570-584.
03-04-2023
Semi-supervised analysis of myeloid and T cell behavior in ex vivo ovarian tumor slices reveals changes in cell motility after treatmentsLaforêts F, Kotantaki P, Malacrida B, Elorbany S, Manchanda R, Donnadieu E and Balkwill F
Iscience, Elsevier vol. 26 (4)
29-03-2023
Interest, Mindsets and Engagement: Longitudinal Relations in Science Orientations for Adolescents in Informal Science ProgramsJoy A, Mathews CJ, Zhao M, Law F, McGuire L, Hoffman AJ, Balkwill F, Burns KP, Butler L, Drews M, Fields G, Smith H, Ozturk E, Winterbottom M, Rutland A, Hartstone-Rose A and Mulvey KL
Journal of Youth and Adolescence, Springer Nature vol. 52 (5), 1088-1099.
06-02-2023
2022
A factorial randomised trial investigating factors influencing general practitioners’ willingness to prescribe aspirin for cancer preventive therapy in Lynch syndrome: a registered reportLloyd KE, Hall LH, Ziegler L, Foy R, Borthwick GM, MacKenzie M, Taylor DG and Smith SG
British Journal of General Practice, Royal College of General Practitioners vol. 73 (729)
14-12-2022
Promoting Diverse Youth’s Career Development through Informal Science Learning: The Role of Inclusivity and BelongingZhao M, Mathews CJ, Mulvey KL, Hartstone-Rose A, McGuire L, Hoffman AJ, Winterbottom M, Joy A, Law F, Balkwill F, Burns KP, Butler L, Drews M, Fields G, Smith H and Rutland A
Journal of Youth and Adolescence, Springer Nature vol. 52 (2), 331-343.
07-11-2022
Gender Stereotypes and Peer Selection in STEM Domains Among Children and AdolescentsMcGuire L, Hoffman AJ, Mulvey KL, Hartstone-Rose A, Winterbottom M, Joy A, Law F, Balkwill F, Burns KP, Butler L, Drews M, Fields G, Smith H and Rutland A
Sex Roles, Springer Nature vol. 87 (9-10), 455-470.
01-11-2022
The tumour microenvironment of clear cell ovarian cancerDevlin M-J, Miller R, Laforets F, Kotantaki P, Garsed DW, Kristeleit R, Bowtell DD, McDermott J, Maniati E and Balkwill FR
Cancer Immunology Research, American Association For Cancer Research (Aacr) vol. 10 (11), 1326-1339.
12-09-2022
A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα, and IL-1βOlivera I, Sanz-Pamplona R, Bolaños E, Rodriguez I, Etxeberria I, Cirella A, Egea J, Garasa S, Migueliz I, Eguren-Santamaria I, Sanmamed MF, Glez-Vaz J, Azpilikueta A, Alvarez M, Ochoa MC, Malacrida B, Propper D, de Andrea CE, Berraondo P, Balkwill FR, Teijeira Á and Melero I
Cancer Discovery, American Association For Cancer Research (Aacr) vol. 12 (9), 2140-2157.
30-06-2022
Abstract 693: TGFβ-mediated targeting of the extracellular matrix enhances the migration and cytotoxicity of CAR-T cells in 3D models of ovarian cancerJoy JD, Malacrida B, Laforêts F, Kotantaki P, Maniati E, Hopkins S, Calleja I, Brett S, Athanasopoulos T, Ali S, Emery-Billcliff P, Ricciardelli I, Kay C, Colebrook J, Ali M, Strong K and Balkwill F
Cancer Research, American Association For Cancer Research (Aacr) vol. 82 (12_Supplement), 693-693.
15-06-2022
Preparing the Next Generation for STEM: Adolescent Profiles Encompassing Math and Science Motivation and Interpersonal Skills and Their Associations With Identity and BelongingMulvey KL, McGuire L, Mathews C, Hoffman AJ, Law F, Joy A, Hartstone-Rose A, Winterbottom M, Balkwill F, Fields G, Butler L, Burns K, Drews M and Rutland A
Youth & Society, Sage Publications vol. 55 (6), 1207-1230.
03-05-2022
Organ-on-a-chip: current gaps and future directionsCandarlioglu PL, Dal Negro G, Hughes D, Balkwill F, Harris K, Screen H, Morgan H, David R, Beken S, Guenat O, Rowan W and Amour A
Biochemical Society Transactions, Portland Press vol. 50 (2), 665-673.
19-04-2022
Immune mechanisms of resistance to cediranib in ovarian cancerDifferential response and resistance to cediranib in HGSOCGopinathan G, Berlato C, Lakhani A, Szabova L, Pegrum C, Pedrosa A-R, Laforets F, Maniati E and Balkwill FR
Molecular Cancer Therapeutics, American Association For Cancer Research (Aacr) vol. 21 (6), 1030-1043.
21-03-2022
Building in vitro 3D human multicellular models of high-grade serous ovarian cancerMalacrida B, Pearce OMT and Balkwill FR
Star Protocols, Elsevier vol. 3 (1)
11-01-2022
Harnessing cytokines and chemokines for cancer therapyPropper DJ and Balkwill FR
Nature Reviews Clinical Oncology, Springer Nature vol. 19 (4), 237-253.
07-01-2022
2021
Stromal Cells Promote Matrix Deposition, Remodelling and an Immunosuppressive Tumour Microenvironment in a 3D Model of Colon CancerLeonard NA, Reidy E, Thompson K, McDermott E, Peerani E, Bort ET, Balkwill FR, Loessner D and Ryan AE
Cancers, Mdpi vol. 13 (23)
29-11-2021
Loss of mTORC2-induced metabolic reprogramming in monocytes uncouples migration and maturation from production of proinflammatory mediatorsJangani M, Vuononvirta J, Yamani L, Ward E, Capasso M, Nadkarni S, Balkwill F and Marelli-Berg F
Journal of Leukocyte Biology, Oxford University Press (Oup) vol. 111 (5), 967-980.
29-09-2021
TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian CancerTGFBI and Ovarian CancerLecker LSM, Berlato C, Maniati E, Delaine-Smith R, Pearce OMT, Heath O, Nichols SJ, Trevisan C, Novak M, McDermott J, Brenton JD, Cutillas PR, Rajeeve V, Hennino A, Drapkin R, Loessner D and Balkwill FR
Cancer Research, American Association For Cancer Research (Aacr) vol. 81 (22), 5706-5719.
24-09-2021
Impact of Youth and Adult Informal Science Educators on Youth Learning at ExhibitsMcGuire L, Hoffman AJ, Mulvey KL, Winterbottom M, Balkwill F, Burns KP, Chatton M, Drews M, Eaves N, Fields GE, Joy A, Law F, Rutland A and Hartstone-Rose A
Visitor Studies, Taylor & Francis vol. 25 (1), 41-59.
13-07-2021
A human multi-cellular model shows how platelets drive production of diseased extracellular matrix and tissue invasionMalacrida B, Nichols S, Maniati E, Jones R, Delanie-Smith R, Roozitalab R, Tyler EJ, Thomas M, Boot G, Mackerodt J, Lockley M, Knight MM, Balkwill FR and Pearce OMT
Iscience, Elsevier vol. 24 (6)
29-05-2021
Modelling TGFβR and Hh pathway regulation of prognostic matrisome molecules in ovarian cancerDelaine-Smith RM, Maniati E, Malacrida B, Nichols S, Roozitalab R, Jones RR, Lecker LSM, Pearce OMT, Knight MM and Balkwill FR
Iscience, Elsevier vol. 24 (6)
29-05-2021
Chemotherapy Induces Tumor-Associated Macrophages that Aid Adaptive Immune Responses in Ovarian CancerHeath O, Berlato C, Maniati E, Lakhani A, Pegrum C, Kotantaki P, Elorbany S, Böhm S, Barry ST, Annibaldi A, Barton DP and Balkwill FR
Cancer Immunology Research, American Association For Cancer Research (Aacr) vol. 9 (6), 665-681.
10-04-2021
Cells are Us – combining research and public engagementBalkwill FR
Nature Reviews Cancer, Springer Nature vol. 21 (5), 277-278.
24-03-2021
Investigating the impact of London’s Ultra Low Emission Zone on children’s health: Children’s Health in London and Luton (CHILL): Protocol for a prospective parallel cohort studyColligan G, Tsocheva I, Scales J, Chavda J, Dove R, Kalsi H, Wood H, Cross L, Newby C, Hall A, Keating M, Petrovic K, Day B, Crichlow C, Keighley A, Thomson A, Tomini F, Balkwill F, Mihaylova B, Grigg J, van Sluijs E, Fletcher M, Mon-Williams M, Wright J, Beevers S, Randhawa G, Eldridge S, Sheikh A, Gauderman J and Kelly F
, Cold Spring Harbor Laboratory
08-02-2021
Modelling TGFβR and Hh pathway regulation of prognostic matrisome molecules in ovarian cancerDelaine-Smith R, Maniati E, Malacrida B, Nichols S, Roozitalab R, Jones R, Lecker L, Pearce O, Knight M and Balkwill F
, Editors: Balkwill F. Biorxiv.Org
02-02-2021
Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in MiceDelvecchio FR, Fincham REA, Spear S, Clear A, Roy-Luzarraga M, Balkwill FR, Gribben JG, Bombardieri M, Hodivala-Dilke K, Capasso M and Kocher HM
Cellular and Molecular Gastroenterology and Hepatology, Elsevier vol. 12 (5), 1543-1565.
01-01-2021
2020
Author Correction: A guiding map for inflammationNetea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, Golenbock D, Gresnigt MS, Heneka MT, Hoffman HM, Hotchkiss R, Joosten LAB, Kastner DL, Korte M, Latz E, Libby P, Mandrup-Poulsen T, Mantovani A, Mills KHG, Nowak KL, O’Neill LA, Pickkers P, van der Poll T, Ridker PM, Schalkwijk J, Schwartz DA, Siegmund B, Steer CJ, Tilg H and van der Meer JWM
Nature Immunology, Springer Nature vol. 22 (2), 254-254.
07-12-2020
Targeting DNA Damage Response and Replication Stress in Pancreatic CancerDreyer SB, Upstill-Goddard R, Paulus-Hock V, Paris C, Lampraki E-M, Dray E, Serrels B, Caligiuri G, Rebus S, Plenker D, Galluzzo Z, Brunton H, Cunningham R, Tesson M, Nourse C, Bailey U-M, Jones M, Moran-Jones K, Wright DW, Duthie F, Oien K, Evers L, McKay CJ, McGregor GA, Gulati A, Brough R, Bajrami I, Pettitt S, Dziubinski ML and Candido J
Gastroenterology, Elsevier vol. 160 (1), 362-377.e13.
09-10-2020
Specific mechanisms of chromosomal instability indicate therapeutic sensitivities in high-grade serous ovarian carcinoma.Mcclelland S, Tamura N, Shaikh N, Muliaditan D, Soliman T, McGuinness J, Maniati E, Moralli D, Durin M-A, Green C, Balkwill F, Wang J and Curtius K
Cancer Research, American Association For Cancer Research
30-09-2020
The role of the tumour microenvironment in pituitary adenoma angiogenesisMarques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, Mendoza N, Muquit S, Dorward N, Grieve J, Balkwill F, Grossman AB and Korbonits M
Endocrine Abstracts, Bioscientifica
21-08-2020
The Relations and Role of Social Competencies and Belonging with Math and Science Interest and Efficacy for Adolescents in Informal STEM ProgramsHoffman AJ, McGuire L, Rutland A, Hartstone-Rose A, Irvin MJ, Winterbottom M, Balkwill F, Fields GE and Mulvey KL
Journal of Youth and Adolescence, Springer Nature vol. 50 (2), 314-323.
17-08-2020
Abstract 4976: Combining measures of immune infiltration uncovers predictors of survival in high-grade serous ovarian cancerMontfort A, Owen SJ, Piskorz AM, Supernat A, Moore L, Al-Khalidi S, Boehm S, Pharoah P, McDermott J, Balkwill FR and Brenton JD
Cancer Research, American Association For Cancer Research (Aacr) vol. 80 (16_Supplement), 4976-4976.
15-08-2020
A Darker Side to Retinoic Acid Revealed by SarcomasBalkwill FR
New England Journal of Medicine, Massachusetts Medical Society vol. 383 (5), 491-493.
30-07-2020
Interest and learning in informal science learning sites: Differences in experiences with different types of educatorsMulvey KL, McGuire L, Hoffman AJ, Goff E, Rutland A, Winterbottom M, Balkwill F, Irvin MJ, Fields GE, Burns K, Drews M, Law F, Joy A and Hartstone-Rose A
Plos One, Public Library of Science (Plos) vol. 15 (7)
23-07-2020
Abstract IA15: Modeling the tumor microenvironment of high-grade serous ovarian cancerBalkwill F
Clinical Cancer Research, American Association For Cancer Research (Aacr) vol. 26 (13_Supplement), ia15-ia15.
01-07-2020
Learning hand in hand: Engaging in research–practice partnerships to advance developmental scienceMulvey KL, McGuire L, Hoffman AJ, Hartstone‐Rose A, Winterbottom M, Balkwill F, Fields GE, Burns K, Drews M, Chatton M, Eaves N, Law F, Joy A and Rutland A
New Directions For Child and Adolescent Development, Hindawi vol. 2020 (172), 125-134.
01-07-2020
Airway dendritic cell maturation in children exposed to air pollutionWhitehouse AL, Mushtaq N, Miyashita L, Barratt B, Khan A, Kalsi H, Koh L, Padovan MG, Brugha R, Balkwill FR, Stagg AJ and Grigg J
Plos One, Public Library of Science (Plos) vol. 15 (5), e0232040-e0232040.
05-05-2020
Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinomaMontfort A, Owen S, Piskorz AM, Supernat A, Moore L, Al-Khalidi S, Böhm S, Pharoah P, McDermott J, Balkwill FR and Brenton JD
British Journal of Cancer, Springer Nature [Academic Journals On Nature.Com]
06-04-2020
Cancer associated fibroblast FAK regulates malignant cell metabolism.Demircioglu F, Wang J, Candido J, Costa ASH, Casado P, de Luxan Delgado B, Reynolds LE, Gomez-Escudero J, Newport E, Rajeeve V, Baker A-M, Roy-Luzarraga M, Graham TA, Foster J, Wang Y, Campbell JJ, Singh R, Zhang P, Schall TJ, Balkwill FR, Sosabowski J, Cutillas PR, Frezza C, Sancho P and Hodivala-Dilke K
Nature Communications, Nature Research (Part of Springer Nature) vol. 11 (1), 1290-1290.
10-03-2020
Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to TreatmentManiati E, Berlato C, Gopinathan G, Heath O, Kotantaki P, Lakhani A, McDermott J, Pegrum C, Delaine-Smith RM, Pearce OMT, Hirani P, Joyce JD, Szabova L, Perets R, Sansom OJ, Drapkin R, Bailey P and Balkwill F
Ssrn Electronic Journal, Elsevier Bv
14-01-2020
2019
Pituitary tumour fibroblast-derived cytokines influence tumour aggressivenessMarques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, Dorward N, Grieve J, Mendoza N, Muquit S, Grossman AB, Balkwill F and Korbonits M
Endocrine Related Cancer, Bioscientifica vol. -1 (aop), 853-865.
01-12-2019
Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumoursMarques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, Dorward N, Grieve J, Mendoza N, Muquit S, Grossman AB, Balkwill F and Korbonits M
Acta Neuropathologica Communications, Springer Nature vol. 7 (1)
08-11-2019
Pituitary tumour-derived chemokines modulate immune cell infiltrates in the tumour microenvironment leading to aggressive phenotypeMarques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, Mendoza N, Dorward N, Grieve J, Balkwill F and Korbonits M
Endocrine Abstracts, Bioscientifica
01-05-2019
MON-462 Cytokine Network in Pituitary Adenomas and Its Role in the Tumor Microenvironment: Focus on MacrophagesMarques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, Dorward N, Grieve J, Balkwill F and Korbonits M
Journal of The Endocrine Society, The Endocrine Society vol. 3 (Supplement_1), mon-462.
15-04-2019
MON-460 Pasireotide Treatment Inhibits Cytokine Release from Pituitary Adenoma-Associated Fibroblasts: Is This Mechanism Playing a Key Role in Its Effect?Marques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, Dorward N, Grieve J, Balkwill F and Korbonits M
Journal of The Endocrine Society, The Endocrine Society vol. 3 (Supplement_1), mon-460.
15-04-2019
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special ConferenceBast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z and Mills GB
Cancer vol. 125 (12), 1963-1972.
05-03-2019
Discrepancies in the tumor microenvironment of spontaneous and orthotopic murine models of pancreatic cancer uncover a new immunostimulatory phenotype for B cellsSpear S, Candido JB, McDermott JR, Ghirelli C, Maniati E, Beers SA, Balkwill FR, Kocher HM and Capasso M
Frontiers in Immunology, Frontiers Media vol. 10 (MAR)
01-01-2019
2018
Characterization of the Extracellular Matrix of Normal and Diseased Tissues Using ProteomicsNaba A, Pearce OMT, Del Rosario A, Ma D, Ding H, Rajeeve V, Cutillas PR, Balkwill FR and Hynes RO
Journal of Proteome Research vol. 16 (8), 3083-3091.
01-12-2018
Mets and NETs: The Awakening ForceSanz-Moreno V and Balkwill FR
Immunity vol. 49 (5), 798-800.
20-11-2018
CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous SubtypeCandido JB, Morton JP, Bailey P, Campbell AD, Karim SA, Jamieson T, Lapienyte L, Gopinathan A, Clark W, McGhee EJ, Wang J, Escorcio-Correia M, Zollinger R, Roshani R, Drew L, Rishi L, Arkell R, Evans TRJ, Nixon C, Jodrell DI, Wilkinson RW, Biankin AV, Barry ST, Balkwill FR and Sansom OJ
Cell Reports, Elsevier vol. 23 (5), 1448-1460.
01-05-2018
2017
Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers.Pearce OMT, Delaine-Smith R, Maniati E, Nichols S, Wang J, Böhm S, Rajeeve V, Ullah D, Chakravarty P, Jones RR, Montfort A, Dowe T, Gribben J, Jones JL, Kocher HM, Serody JS, Vincent BG, Connelly J, Brenton JD, Chelala C, Cutillas PR, Lockley M, Bessant C, Knight M and Balkwill FR
Cancer Discov
01-12-2017
A guiding map for inflammation.Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, Golenbock D, Gresnigt MS, Heneka MT, Hoffman HM, Hotchkiss R, Joosten LAB, Kastner DL, Korte M, Latz E, Libby P, Mandrup-Poulsen T, Mantovani A, Mills KHG, Nowak KL, O'Neill LA, Pickkers P, van der Poll T, Ridker PM, Schalkwijk J, Schwartz DA, Siegmund B, Steer CJ, Tilg H and van der Meer JWM
Nat Immunol vol. 18 (8), 826-831.
19-07-2017
A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancerBALKWILL F, Berlato C, Khan MN, Schioppa T, Thompson R, Maniati E, Montfort A, Jangani M, Canosa M, Kulbe H, Hagemann U, Duncan A, Fletcher L, Wilkinson RW, Powles T and Quezada S
Journal of Clinical Investigation, American Society For Clinical Investigation
30-01-2017
2016
CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high grade serous carcinomaWalton J, Blagih J, Ennis D, Leung E, Dowson S, Farquharson M, Tookman LA, Orange C, Athineos D, Mason S, Stevenson D, Blyth K, Strathdee D, Balkwill FR, Vousden KH, Lockley M and McNeish IA
Cancer Research, American Association For Cancer Research
16-08-2016
Experimental validation of a flat punch indentation methodology calibrated against unconfined compression tests for determination of soft tissue biomechanicsDelaine-Smith RM, Burney S, Balkwill FR and Knight MM
Journal of The Mechanical Behavior of Biomedical Materials, Elsevier vol. 60, 401-415.
01-07-2016
A strong B cell response is part of the immune landscape in human high-grade serous ovarian metastases.Montfort A, Pearce OMT, Maniati E, Vincent B, Bixby LM, Bo hm S, Dowe T, Wilkes EH, Chakravarty P, Thompson R, Topping J, Cutillas PR, Lockley M, Serody JS, Capasso M and Balkwill FR
Clinical Cancer Research, American Association For Cancer Research
27-06-2016
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal AdenocarcinomaSteele CW, Karim SA, Leach JDG, Bailey P, Upstill-Goddard R, Rishi L, Foth M, Bryson S, McDaid K, Wilson Z, Eberlein C, Candido JB, Clarke M, Nixon C, Connelly J, Jamieson N, Carter CR, Balkwill F, Chang DK, Evans TRJ, Strathdee D, Biankin AV, Nibbs RJB, Barry ST, Sansom OJ and Morton JP
Cancer Cell, Elsevier (Cell Press) vol. 29 (6), 832-845.
13-06-2016
Reduced expression of histone methyltransferases KMT2C and KMT2D correlates with improved outcome in pancreatic ductal adenocarcinomaGROSE RP, Dawkins JBN, Wang J, maniati , heward , koniali , kocher , martin , chelala , balkwill and fitzgibbon
Cancer Research, American Association For Cancer Research
10-06-2016
Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinomaBALKWILL F, Anne Montfort and Oliver Pearce
Clinical Cancer Research, American Association For Cancer Research
01-04-2016
Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cellsKulbe H, Iorio F, Chakravarty P, Milagre CS, Moore R, Thompson RG, Everitt G, Canosa M, Montoya A, Drygin D, Braicu I, Sehouli J, Saez-Rodriguez J, Cutillas PR and Balkwill FR
Oncotarget, Impact Journals vol. 7 (13), 15648-15661.
08-02-2016
Abstract B53: CRISPR/Cas9 mediated p53 and BRCA2 knockout to generate improved murine models of high grade serous ovarian cancer.Walton J, Dowson S, Ennis D, Leung E, Farquharson M, Stevenson D, Blyth K, Strathdee D, Balkwill FR, Lockley M and McNeish IA
Clinical Cancer Research, American Association For Cancer Research (Aacr) vol. 22 (2_Supplement), b53-b53.
15-01-2016
2015
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerBowtell DD, Böhm S, Ahmed AA, Aspuria P-J, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA and Menon U
Nature Reviews Cancer, Springer Nature vol. 15 (11), 668-679.
23-10-2015
Centre of the Cell: Science Comes to LifeBalkwill F and Chambers K
Plos Biology, Public Library of Science (Plos) vol. 13 (9)
04-09-2015
Interleukin-6 Stimulates Defective AngiogenesisGopinathan G, Milagre C, Pearce OMT, Reynolds LE, Hodivala-Dilke K, Leinster DA, Zhong H, Hollingsworth RE, Thompson R, Whiteford JR and Balkwill F
Cancer Research, American Association For Cancer Research (Aacr) vol. 75 (15), 3098-3107.
01-08-2015
Abstract 4162: Interleukin–6 stimulates defective angiogenesisGopinathan G, Milagre C, Pearce OMT, Reynolds L, Hodivala-Dilke K, Leinster A, Zhong H, Hollingsworth RE, Thompson R, Whiteford JR and Balkwill F
Cancer Research, American Association For Cancer Research (Aacr) vol. 75 (15_Supplement), 4162-4162.
01-08-2015
Inflammation and cancer: advances and new agentsCrusz SM and Balkwill FR
Nature Reviews Clinical Oncology, Springer Nature vol. 12 (10), 584-596.
30-06-2015
Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian CancerMilagre CS, Gopinathan G, Everitt G, Thompson RG, Kulbe H, Zhong H, Hollingsworth RE, Grose R, Bowtell DDL, Hochhauser D and Balkwill FR
Cancer Research, American Association For Cancer Research (Aacr) vol. 75 (7), 1255-1264.
31-03-2015
Targeting inflammatory cytokines in cancerBalkwill F
Clinical & Experimental Metastasis vol. 32 (3), 183-183.
01-01-2015
2014
Murine CD27(-) Vγ6(+) γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages.Rei M, Gonçalves-Sousa N, Lança T, Thompson RG, Mensurado S, Balkwill FR, Kulbe H, Pennington DJ and Silva-Santos B
Proc Natl Acad Sci U S A vol. 111 (34), E3562-E3570.
26-08-2014
33: Targeting cancer-related inflammationBalkwill F
European Journal of Cancer, Elsevier vol. 50
01-07-2014
Chemotherapy, immunity and microbiota--a new triumvirate?Karin M, Jobin C and Balkwill F
Nat Med vol. 20 (2), 126-127.
01-02-2014
Cancer cell-derived lymphotoxin mediates reciprocal tumour-stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts.Lau T-S, Chung TK-H, Cheung T-H, Chan LK-Y, Cheung LW-H, Yim S-F, Siu NS-S, Lo K-W, Yu MM-Y, Kulbe H, Balkwill FR and Kwong J
J Pathol vol. 232 (1), 43-56.
01-01-2014
2013
Vaccinia virus induces programmed necrosis in ovarian cancer cells.Whilding LM, Archibald KM, Kulbe H, Balkwill FR, Öberg D and McNeish IA
Mol Ther vol. 21 (11), 2074-2086.
01-11-2013
Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer.Leinster DA, Colom B, Whiteford JR, Ennis DP, Lockley M, McNeish IA, Aurrand-Lions M, Chavakis T, Imhof BA, Balkwill FR and Nourshargh S
Faseb J vol. 27 (10), 4244-4253.
01-10-2013
B regulatory cells in cancer.Balkwill F, Montfort A and Capasso M
Trends Immunol vol. 34 (4), 169-173.
01-04-2013
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.Sandhu SK, Papadopoulos K, Fong PC, Patnaik A, Messiou C, Olmos D, Wang G, Tromp BJ, Puchalski TA, Balkwill F, Berns B, Seetharam S, de Bono JS and Tolcher AW
Cancer Chemother Pharmacol vol. 71 (4), 1041-1050.
01-04-2013
2012
The tumor microenvironment at a glance.Balkwill FR, Capasso M and Hagemann T
J Cell Sci vol. 125 (Pt 23), 5591-5596.
01-12-2012
Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium.Archibald KM, Kulbe H, Kwong J, Chakravarty P, Temple J, Chaplin T, Flak MB, McNeish IA, Deen S, Brenton JD, Young BD and Balkwill F
Oncogene vol. 31 (48), 4987-4995.
29-11-2012
The peritoneal tumour microenvironment of high-grade serous ovarian cancer.Leinster DA, Kulbe H, Everitt G, Thompson R, Perretti M, Gavins FNE, Cooper D, Gould D, Ennis DP, Lockley M, McNeish IA, Nourshargh S and Balkwill FR
J Pathol vol. 227 (2), 136-145.
01-06-2012
Abstract 4391: CD20 as a target for therapy in solid tumorsAffara NI, Ruffell B, Johansson M, Fujikawa K, Bergsland E, DeNardo DG, Chen HI, Wadhwani N, Steinhoff M, Truitt M, Olson P, Hanahan D, Li Y, Gong Q, Ma Y, Wiesen JF, Kim G, Tempero M, Balkwill F, Irving B and Coussens LM
Cancer Research, American Association For Cancer Research (Aacr) vol. 72 (8_Supplement), 4391-4391.
15-04-2012
Abstract 49: Targeting the TNF network in human ovarian cancer - A systems biology approachKulbe H, Chakravarty P, Moore R, Iorio F, Montoya A, Saez-Rodriguez J, Cutillas P and Balkwill F
Cancer Research, American Association For Cancer Research (Aacr) vol. 72 (8_Supplement), 49-49.
15-04-2012
Paraneoplastic thrombocytosis in ovarian cancer.Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MMK, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K and Lutgendorf SK
N Engl J Med vol. 366 (7), 610-618.
16-02-2012
Cancer-related inflammation: common themes and therapeutic opportunities.Balkwill FR and Mantovani A
Semin Cancer Biol vol. 22 (1), 33-40.
01-02-2012
A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment.Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, Schioppa T, Robinson SC, Gallagher WM, Galletta L, Australian Ovarian Cancer Study Group , Salako MA, Smyth JF, Hagemann T, Brennan DJ, Bowtell DD and Balkwill FR
Cancer Res vol. 72 (1), 66-75.
01-01-2012
2011
IL-6 and ovarian cancer--response.Balkwill FR, Coward J, Kulbe H, Milagre C, Gopinathan G and McNeish IA
Clin Cancer Res vol. 17 (24)
15-12-2011
Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice.Maniati E, Bossard M, Cook N, Candido JB, Emami-Shahri N, Nedospasov SA, Balkwill FR, Tuveson DA and Hagemann T
J Clin Invest vol. 121 (12), 4685-4699.
01-12-2011
Rethinking ovarian cancer: recommendations for improving outcomes.Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD and Balkwill FR
Nat Rev Cancer vol. 11 (10), 719-725.
23-09-2011
Interleukin-6 as a therapeutic target in human ovarian cancer.Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J, Singh N, Avril N, Cummings J, Rexhepaj E, Jirström K, Gallagher WM, Brennan DJ, McNeish IA and Balkwill FR
Clin Cancer Res vol. 17 (18), 6083-6096.
15-09-2011
Safety of medicines and the use of animals in research.Balkwill F, Whitehead S, Willis P, Gaymond N, Kent A, Page C, Lovell-Badge R, Morris R, Lemon R and Banks D
Lancet vol. 378 (9786), 127-128.
09-07-2011
B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis.Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM and Balkwill FR
Proc Natl Acad Sci U S A vol. 108 (26), 10662-10667.
28-06-2011
Translating science in more ways than one: an interview with Frances BalkwillAllan S and Balkwill F
Dis Model Mech vol. 4 (3), 286-288.
01-05-2011
Deciphering the Genetic Predisposition to Primary Sclerosing CholangitisKarlsen T and Kaser A
Seminars in Liver Disease, Thieme vol. 31 (02), 188-207.
01-05-2011
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG, Australian Ovarian Cancer Study Group , Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, Gilks CB and Bowtell DD
Clin Cancer Res vol. 17 (8), 2538-2548.
15-04-2011
Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.Salako MA, Kulbe H, Ingemarsdotter CK, Pirlo KJ, Williams SL, Lockley M, Balkwill FR and McNeish IA
Mol Ther vol. 19 (3), 490-499.
01-03-2011
2010
TNF: a tumor-suppressing factor or a tumor-promoting factor?Balkwill F and Joffroy C
Future Oncol vol. 6 (12), 1833-1836.
01-12-2010
Targeting Inflammatory Pathways in Epithelial Ovarian CancerCoward J and Balkwill F
In Emerging Therapeutic Targets in Ovarian Cancer, Springer Nature 133-164.
23-10-2010
The Inflammatory Tissue Microenvironment and the Early Stages of MalignancyBalkwill F
In Pre-Invasive Disease: Pathogenesis and Clinical Management, Springer Nature 21-29.
26-08-2010
p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker.Flak MB, Connell CM, Chelala C, Archibald K, Salako MA, Pirlo KJ, Lockley M, Wheatley SP, Balkwill FR and McNeish IA
Mol Cancer vol. 9
03-07-2010
Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells.Toulza F, Nosaka K, Tanaka Y, Schioppa T, Balkwill F, Taylor GP and Bangham CRM
J Immunol vol. 185 (1), 183-189.
01-07-2010
Guidelines for the welfare and use of animals in cancer research.Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DAH, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA and Committee of the National Cancer Research Institute
Br J Cancer vol. 102 (11), 1555-1577.
25-05-2010
Cancer and inflammation: implications for pharmacology and therapeutics.Balkwill F and Mantovani A
Clin Pharmacol Ther vol. 87 (4), 401-406.
01-04-2010
Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers.Saadi A, Shannon NB, Lao-Sirieix P, O'Donovan M, Walker E, Clemons NJ, Hardwick JS, Zhang C, Das M, Save V, Novelli M, Balkwill F and Fitzgerald RC
Proc Natl Acad Sci U S A vol. 107 (5), 2177-2182.
02-02-2010
2009
The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans.Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P, Thompson RG, Kollias G, Smyth JF, Balkwill FR and Hagemann T
J Clin Invest vol. 119 (10), 3011-3023.
01-10-2009
An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells.Kwong J, Kulbe H, Wong D, Chakravarty P and Balkwill F
Mol Cancer Ther vol. 8 (7), 1893-1905.
01-07-2009
Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells.Kwong J, Chan FL, Wong K-K, Birrer MJ, Archibald KM, Balkwill FR, Berkowitz RS and Mok SC
Neoplasia vol. 11 (6), 529-541.
01-06-2009
A novel function of colony-stimulating factor 1 receptor in hTERT immortalization of human epithelial cells.Li NF, Kocher HM, Salako MA, Obermueller E, Sandle J and Balkwill F
Oncogene vol. 28 (5), 773-780.
05-02-2009
Spontaneously transformed hTERT immortalized human ovarian surface epithelial cells have a functional amplification of the CXCR4 gene locusArchibald K, Kwong J, Kulbe H, Young B and Balkwill F
Cancer Research vol. 69
01-01-2009
A Phase II study of intravenous CNT0328 in patients with recurrent epithelial ovarian cancerCoward J, Quigley M, Leader D, Berns B, Balkwill F and McNeish I
Cancer Research vol. 69
01-01-2009
Role of B cell in two-stage skin carcinogenesisSchioppa T, Moore R, Thompson R, de Visser K, Coussens L and Balkwill F
Cancer Research vol. 69
01-01-2009
2008
Cancer-related inflammation.Mantovani A, Allavena P, Sica A and Balkwill F
Nature vol. 454 (7203), 436-444.
24-07-2008
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancerBrown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, Vora R, Prabhakar U, Nakada M, Corringham RE, DeWitte M, Sturgeon C, Propper D, Balkwill FR and Smyth JF
Ann Oncol vol. 19 (7), 1340-1346.
01-07-2008
Re-educating tumor-associated macrophages by targeting NF-kappaB.Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC and Balkwill FR
J Exp Med vol. 205 (6), 1261-1268.
09-06-2008
Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007Ashworth A, Balkwill F, Bast RC, Berek JS, Kaye A, Boyd JA, Mills G, Weinstein JN, Woolley K and Workman P
Gynecol Oncol vol. 108 (3), 652-657.
01-03-2008
Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cellsKaragiannis SN, Bracher MG, Beavil RL, Beavil AJ, Hunt J, McCloskey N, Thompson RG, East N, Burke F, Sutton BJ, Dombrowicz D, Balkwill FR and Gould HJ
Cancer Immunol Immun vol. 57 (2), 247-263.
01-02-2008
2007
Human ovarian surface epithelial cells immortalized with hTERT maintain functional pRb and p53 expression.Li NF, Broad S, Lu YJ, Yang JS, Watson R, Hagemann T, Wilbanks G, Jacobs I, Balkwill F, Dafou D and Gayther SA
Cell Prolif vol. 40 (5), 780-794.
01-10-2007
Inflammation and cancer: A double-edged swordHagemann T, Balkwill F and Lawrence T
Cancer Cell vol. 12 (4), 300-301.
01-10-2007
IgE-antibody-dependent immunotherapy of solid tumors: Cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cellsKaragiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, Beavil AJ, Fear DJ, Thompson RG, East N, Burke F, Moore RJ, Dombrowicz DD, Balkwill FR and Gould HJ
J Immunol vol. 179 (5), 2832-2843.
01-09-2007
Cancer. Sex, cytokines, and cancer.Lawrence T, Hageman T and Balkwill F
Science vol. 317 (5834), 51-52.
06-07-2007
Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer.Szlosarek PW, Grimshaw MJ, Wilbanks GD, Hagemann T, Wilson JL, Burke F, Stamp G and Balkwill FR
Int J Cancer vol. 121 (1), 6-11.
01-07-2007
Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis.Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H and Balkwill FR
Mol Cancer Ther vol. 6 (7), 1993-2002.
01-07-2007
The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cellsKulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, Gould D, Ayhan A and Balkwill F
Cancer Res vol. 67 (2), 585-592.
15-01-2007
2006
In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletionSzlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, Grimshaw MJ, Steele JP, Rudd RM, Balkwill FR and Fennell DA
Clin Cancer Res vol. 12 (23), 7126-7131.
01-12-2006
RaIB signaling: A bridge between inflammation and cancerMantovani A and Balkwill F
Cell vol. 127 (1), 42-44.
06-10-2006
TNF-alpha in promotion and progression of cancer.Balkwill F
Cancer Metastasis Rev vol. 25 (3), 409-416.
01-09-2006
Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S, Millard L, Rohatiner A, Boral A, Trehu E, Schenkein D, Balkwill F, Joel SP and Lister TA
J Clin Oncol vol. 24 (13), 2105-2112.
01-05-2006
Ovarian cancer cells polarize macrophages towards a tumor-associated phenotypeHagemann T, Wilson J, Burke F, Kulbe H, Li NF, Pluddemann A, Charles K, Gordon S and Balkwill FR
Med Klin vol. 101 (4), A44-A44.
15-04-2006
Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype.Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Plüddemann A, Charles K, Gordon S and Balkwill FR
J Immunol vol. 176 (8), 5023-5032.
15-04-2006
Tumour necrosis factor-alpha as a tumour promoter.Szlosarek P, Charles KA and Balkwill FR
Eur J Cancer vol. 42 (6), 745-750.
01-04-2006
10th Biennial Helene Harris Memorial Trust meeting.Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME, Hamilton TC, Jacobs IJ, Kaye SB, Kohn EC, Mills GB and Urban ND
Cancer Res vol. 66 (6), 2904-2906.
15-03-2006
Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epitheliumSzlosarek PW, Grimshaw MJ, Kulbe H, Wilson JL, Wilbanks GD, Burke F and Balkwill FR
Mol Cancer Ther vol. 5 (2), 382-390.
01-02-2006
2005
Book ReviewBalkwill F
New England Journal of Medicine, Massachusetts Medical Society vol. 353 (22), 2413-2414.
01-12-2005
The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cellsKulbe H, Hagemann T, Szlosarek PW, Balkwill FR and Wilson JL
Cancer Res vol. 65 (22), 10355-10362.
15-11-2005
Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer.Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F and Ganesan TS
J Clin Oncol vol. 23 (25), 5950-5959.
01-09-2005
Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK.Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C and Balkwill FR
J Immunol vol. 175 (2), 1197-1205.
15-07-2005
Involvement of both intrinsic and extrinsic pathways in IFN-gamma-induced apoptosis that are enhanced with cisplatin.Barton C, Davies D, Balkwill F and Burke F
Eur J Cancer vol. 41 (10), 1474-1486.
01-07-2005
The language of life: How cells communicate in health and diseaseBalkwill F
Nature vol. 435 (7046), 1162-1162.
30-06-2005
Smoldering and polarized inflammation in the initiation and promotion of malignant diseaseBalkwill F, Charles KA and Mantovani A
Cancer Cell vol. 7 (3), 211-217.
01-03-2005
2004
A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.Madhusudan S, Foster M, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Talbot DC, Ganesan TS and Harris AL
Clin Cancer Res vol. 10 (19), 6528-6534.
01-10-2004
TNF-alpha regulates epithelial expression of MMP-9 and integrin alphavbeta6 during tumour promotion. A role for TNF-alpha in keratinocyte migration?Scott KA, Arnott CH, Robinson SC, Moore RJ, Thompson RG, Marshall JF and Balkwill FR
Oncogene vol. 23 (41), 6954-6966.
09-09-2004
Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases.Hagemann T, Robinson SC, Schulz M, Trümper L, Balkwill FR and Binder C
Carcinogenesis vol. 25 (8), 1543-1549.
01-08-2004
Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer.Jones PH, Christodoulos K, Dobbs N, Thavasu P, Balkwill F, Blann AD, Caine GJ, Kumar S, Kakkar AJ, Gompertz N, Talbot DC, Ganesan TS and Harris AL
Br J Cancer vol. 91 (1), 30-36.
05-07-2004
A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro.Li NF, Wilbanks G, Balkwill F, Jacobs IJ, Dafou D and Gayther SA
Lab Invest vol. 84 (7), 923-931.
01-07-2004
The significance of cancer cell expression of the chemokine receptor CXCR4Balkwill F
Semin Cancer Biol vol. 14 (3), 171-179.
01-06-2004
A role for endothelin-2 and its receptors in breast tumor cell invasion.Grimshaw MJ, Hagemann T, Ayhan A, Gillett CE, Binder C and Balkwill FR
Cancer Res vol. 64 (7), 2461-2468.
01-04-2004
Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development.Arnott CH, Scott KA, Moore RJ, Robinson SC, Thompson RG and Balkwill FR
Oncogene vol. 23 (10), 1902-1910.
11-03-2004
Current research and treatment for epithelial ovarian cancer. A position paper from the Helene Harris Memorial Trust (vol 39, pg 1818, 2003)Balkwill F, Bast RC, Berek J, Chenevix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G, Souhami R, Urban N, Orsulic S and Smyth J
Eur J Cancer vol. 40 (4), 628-628.
01-03-2004
The chemokine network in cancer - much more than directing cell movementKulbe H, Levinson NR, Balkwill F and Wilson JL
Int J Dev Biol vol. 48 (5-6), 489-496.
01-01-2004
The inflammatory cytokine network of epithelial cancer: therapeutic implications.Szlosarek P and Balkwill F
Novartis Found Symp vol. 256, 227-237.
01-01-2004
2003
A chemokine receptor antagonist inhibits experimental breast tumor growth.Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AEI and Balkwill FR
Cancer Res vol. 63 (23), 8360-8365.
01-12-2003
A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancerMadhusudan S, Protheroe A, Propper D, Han C, Corrie P, Earl H, Hancock B, Vasey P, Turner A, Balkwill F, Hoare S and Harris AL
Brit J Cancer vol. 89 (8), 1418-1422.
20-10-2003
Tumour necrosis factor alpha: a potential target for the therapy of solid tumours.Szlosarek PW and Balkwill FR
Lancet Oncol vol. 4 (9), 565-573.
01-09-2003
Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust.Balkwill F, Bast RC, Berek J, Chenevix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G, Souhami R, Urban N, Orsulic S and Smyth J
Eur J Cancer vol. 39 (13), 1818-1827.
01-09-2003
IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro.Wall L, Burke F, Barton C, Smyth J and Balkwill F
Clin Cancer Res vol. 9 (7), 2487-2496.
01-07-2003
IFN-γ induces apoptosis in ovarian cancer cells in vivo and in vitroWall L, Burke F, Barton C, Smyth J and Balkwill F
Clinical Cancer Research vol. 9 (7), 2487-2496.
01-07-2003
An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors.Scott KA, Moore RJ, Arnott CH, East N, Thompson RG, Scallon BJ, Shealy DJ and Balkwill FR
Mol Cancer Ther vol. 2 (5), 445-451.
01-05-2003
Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cellsKaragiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, Thompson RG, Durham SR, Schwartz LB, Balkwill FR and Gould HJ
Eur J Immunol vol. 33 (4), 1030-1040.
01-04-2003
The anti-proliferative activity of interferon-gamma on ovarian cancer: in vitro and in vivo.Wall L, Burke F, Smyth JF and Balkwill F
Gynecologic Oncology vol. 88 (1 Pt 2)
01-01-2003
Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanomaPropper DJ, Chao D, Braybrooke JP, Bahl P, Thavasu P, Balkwill F, Turley H, Dobbs N, Gatter K, Talbot DC, Harris AL and Ganesan TS
Clin Cancer Res vol. 9 (1), 84-92.
01-01-2003
2002
Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells.Grimshaw MJ, Naylor S and Balkwill FR
Mol Cancer Ther vol. 1 (14), 1273-1281.
01-12-2002
Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancerScotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S, Bridger G and Balkwill FR
Cancer Res vol. 62 (20), 5930-5938.
15-10-2002
Endothelin-2 is a macrophage chemoattractant: Implications for macrophage distribution in tumorsGrimshaw MJ, Wilson JL and Balkwill FR
European Journal of Immunology vol. 32 (9), 2393-2400.
01-09-2002
Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumorsGrimshaw MJ, Wilson JL and Balkwill FR
Eur J Immunol vol. 32 (9), 2393-2400.
01-09-2002
Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway.Arnott CH, Scott KA, Moore RJ, Hewer A, Phillips DH, Parker P, Balkwill FR and Owens DM
Oncogene vol. 21 (31), 4728-4738.
18-07-2002
Cytokines and infections: good, bad and effective therapies?Balkwill F
Trends in Immunology, Elsevier vol. 23 (7)
01-07-2002
A phase II trial using etanercept, a recombinant tumour necrosis factor antagonist, in metastatic breast cancerForster MD, Braybrooke J, Madhusudan S, Kaur K, Hoare S, Balkwill F, Ganesan TS, Talbot D and Harris AL
Brit J Cancer vol. 86, S38-S38.
01-06-2002
Characterisation of the cell content of malignant ascites in advanced epithelial ovarian cancer and clinico-pathological correlationsWall L, Burke F, Smyth J and Balkwill F
Brit J Cancer vol. 86, S45-S46.
01-06-2002
Analysis of chemokines and chemokine receptor expression in ovarian cancer ascitesMilliken D, Scotton C, Raju S, Balkwill F and Wilson J
Clin Cancer Res vol. 8 (4), 1108-1114.
01-04-2002
Tumor necrosis factor or tumor promoting factor?Balkwill F
Cytokine Growth Factor Rev vol. 13 (2), 135-141.
01-04-2002
The role of cytokines in the epithelial cancer microenvironmentWilson J and Balkwill F
Semin Cancer Biol vol. 12 (2), 113-120.
01-04-2002
Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-αRobinson SC, Scott KA and Balkwill FR
European Journal of Immunology vol. 32 (2), 404-412.
07-03-2002
Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha.Robinson SC, Scott KA and Balkwill FR
Eur J Immunol vol. 32 (2), 404-412.
01-02-2002
2001
Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours.Scotton C, Milliken D, Wilson J, Raju S and Balkwill F
Br J Cancer vol. 85 (6), 891-897.
14-09-2001
Epithelial cancer cell migration: a role for chemokine receptors?Scotton CJ, Wilson JL, Milliken D, Stamp G and Balkwill FR
Cancer Res vol. 61 (13), 4961-4965.
01-07-2001
Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation - A potential mechanismGrimsha MJ and Balkwill FR
Brit J Cancer vol. 85, 19-19.
01-07-2001
Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation - A potential mechanismGrimshaw MJ and Balkwill FR
European Journal of Immunology vol. 31 (2), 480-489.
03-03-2001
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP, Caponigro F, Graf P, Dutreix C, Blackie R, Kaye SB, Ganesan TS, Talbot DC, Harris AL and Twelves C
J Clin Oncol vol. 19 (5), 1485-1492.
01-03-2001
Inflammation and cancer: back to Virchow?Balkwill F and Mantovani A
Lancet vol. 357 (9255), 539-545.
17-02-2001
Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation - a potential mechanismGrimshaw MJ and Balkwill FR
Eur J Immunol vol. 31 (2), 480-489.
01-02-2001
2000
Barrett's metaplasiaJankowski JA, Harrison RF, Perry I, Balkwill F and Tselepis C
Lancet vol. 356 (9247), 2079-2085.
16-12-2000
Exploiting changes in the tumour microenvironment with sequential cytokine and matrix metalloprotease inhibitor treatment in a murine breast cancer modelScott KA, Holdsworth H, Balkwill FR and Dias S
British Journal of Cancer, Springer Nature vol. 83 (11), 1538-1543.
14-11-2000
Re: Possible Role of Ovarian Epithelial Inflammation in Ovarian CancerBalkwill FR
Journal of The National Cancer Institute, Oxford University Press (Oup) vol. 92 (2), 162a-1163.
19-01-2000
Defective Expression of the Monocyte Chemotactic Protein-1 Receptor CCR2 in Macrophages Associated with Human Ovarian CarcinomaSica A, Saccani A, Bottazzi B, Bernasconi S, Allavena P, Gaetano B, Fei F, LaRosa G, Scotton C, Balkwill F and Mantovani A
The Journal of Immunology, The American Association of Immunologists vol. 164 (2), 733-738.
15-01-2000
1999
Erratum to “Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis”Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M, Kollias G and Balkwill F
Nature Medicine, Springer Nature vol. 5 (9), 1087-1087.
01-09-1999
The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients.Thavasu P, Propper D, McDonald A, Dobbs N, Ganesan T, Talbot D, Braybrook J, Caponigro F, Hutchison C, Twelves C, Man A, Fabbro D, Harris A and Balkwill F
Cancer Research vol. 59 (16), 3980-3984.
15-08-1999
Hypoxia inhibits macrophage migrationTurner L, Scotton C, Negus R and Balkwill F
European Journal of Immunology vol. 29 (7), 2280-2287.
17-07-1999
Hypoxia inhibits macrophage migrationTurner L, Scotton C, Negus R and Balkwill F
European Journal of Immunology, Wiley vol. 29 (7), 2280-2287.
01-07-1999
Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesisMoore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M, Kollias G and Balkwill F
Nature Medicine, Springer Nature vol. 5 (7), 828-831.
01-07-1999
Cytotoxic response of ovarian cancer cell lines to IFN-γ is associated with sustained induction of IRF-1 and p21 mRNABurke F, Smith PD, Crompton MR, Upton C and Balkwill FR
British Journal of Cancer, Springer Nature vol. 80 (8), 1236-1244.
28-05-1999
MMP-2 release and activation in ovarian carcinoma: the role of fibroblastsBoyd RS and Balkwill FR
British Journal of Cancer, Springer Nature vol. 80 (3-4), 315-321.
09-04-1999
1998
IL‐12 regulates VEGF and MMPs in a murine breast cancer modelDias S, Boyd R and Balkwill F
International Journal of Cancer, Wiley vol. 78 (3), 361-365.
29-10-1998
IL-12 regulates VEGF and MMPs in a murine breast cancer modelDias S, Boyd R and Balkwill F
International Journal of Cancer vol. 78 (3), 361-365.
29-10-1998
Regulation of monocyte MMP-9 production by TNF-α and a tumour-derived soluble factor (MMPSF)Leber T and Balkwill F
British Journal of Cancer, Springer Nature vol. 78 (6), 724-732.
01-09-1998
Hypoxia down-regulates MCP-1 expression: implications for macrophage distribution in tumorsNegus RPM, Turner L, Burke F and Balkwill FR
Journal of Leukocyte Biology, Oxford University Press (Oup) vol. 63 (6), 758-765.
01-06-1998
Multiple molecular and cellular changes associated with tumour stasis and regression during IL‐12 therapy of a murine breast cancer modelDias S, Thomas H and Balkwill F
International Journal of Cancer, Wiley vol. 75 (1), 151-157.
05-01-1998
Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer modelDias S, Thomas H and Balkwill F
International Journal of Cancer vol. 75 (1), 151-157.
05-01-1998
The molecular and cellular biology of the chemokinesBalkwill F
Journal of Viral Hepatitis, Wiley vol. 5 (1), 1-14.
01-01-1998
United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition)British Journal of Cancer, Springer Nature vol. 77 (1), 1-10.
01-01-1998
1997
Cytokine amplification and inhibition of immune and inflammatory responsesBalkwill F
Journal of Viral Hepatitis, Wiley vol. 4 (s2), 6-15.
01-11-1997
Zymography: A Single-Step Staining Method for Quantitation of Proteolytic Activity on Substrate GelsLeber TM and Balkwill FR
Analytical Biochemistry, Elsevier vol. 249 (1), 24-28.
01-06-1997
Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: Enhancement of effect by batimastatBurke F, East N, Upton C, Patel K and Balkwill FR
European Journal of Cancer, Elsevier vol. 33 (7), 1114-1121.
01-06-1997
Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines.Negus RP, Stamp GW, Hadley J and Balkwill FR
American Journal of Pathology vol. 150 (5), 1723-1734.
01-05-1997
1996
Cytokines in animal models of cancerBurke F and Balkwill FR
Biotherapy, Springer Nature vol. 8 (3-4), 229-241.
01-09-1996
Correspondence re: N-B. Liabakk et al., matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res., 56: 190-196, 1966.Zucker S
Cancer Research vol. 56 (15)
01-08-1996
A CYTOKINE PROFILE OF NORMAL AND MALIGNANT OVARYBurke F, Relf M, Negus R and Balkwill F
Cytokine, Elsevier vol. 8 (7), 578-585.
01-07-1996
Cytokines in tumour growth, migration and metastasisNegus RPM and Balkwill FR
World Journal of Urology, Springer Nature vol. 14 (3), 157-165.
01-06-1996
Cytokines in Hemopoiesis, Oncology, and Immunology IIIBalkwill FR
British Journal of Cancer, Springer Nature vol. 73 (5), 711-711.
01-03-1996
Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer.Liabakk NB, Talbot I, Smith RA, Wilkinson K and Balkwill F
Cancer Research vol. 56 (1), 190-196.
01-01-1996
An inbred colony of oncogene transgenic mice: diversity of tumours and potential as a therapeutic modelThomas H, Hanby A, Smith R-A, Hagger P, Patel K, Raikundalia B, Camplejohn R and Balkwill F
British Journal of Cancer, Springer Nature vol. 73 (1), 65-72.
01-01-1996
1995
Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosisde Kossodo S, Moore R, Gschmeissner S, East N, Upton C and Balkwill F
British Journal of Cancer, Springer Nature vol. 72 (5), 1165-1172.
01-11-1995
Assessing new anti-tumour agents and strategies in oncogene transgenic miceThomas H and Balkwill F
Cancer and Metastasis Reviews, Springer Nature vol. 14 (2), 91-95.
01-06-1995
Inhibitory cytokines and cytokine inhibitorsBurger D and Dayer J-M
Neurology, Wolters Kluwer vol. 45 (6), s39-s43.
01-06-1995
The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer.Negus RP, Stamp GW, Relf MG, Burke F, Malik ST, Bernasconi S, Allavena P, Sozzani S, Mantovani A and Balkwill FR
Journal of Clinical Investigation, American Society For Clinical Investigation vol. 95 (5), 2391-2396.
01-05-1995
THE role of indoleamine 2,3‐dioxygenase in the anti‐tumour activity of human interferon‐γ in vivoBurke F, Knowles RG, East N and Balkwill FR
International Journal of Cancer, Wiley vol. 60 (1), 115-122.
03-01-1995
Multiple myeloma: An immunoclinical study of disease and response to treatmentThavasu PW, Ganjoo RK, Maidment SA, Love SB, Williams AH, Malplas JS and Balkwill FR
Hematological Oncology, Wiley vol. 13 (2), 69-82.
01-01-1995
1994
Expression and activity of MMPS and their regulators in ovarian cancerNaylor MS, Stamp GW, Davies BD and Balkwill FR
International Journal of Cancer, Wiley vol. 58 (1), 50-56.
01-07-1994
Association between biosynthesis of nitric oxide and changes in immunological and vascular parameters in patients treated with interleukin‐2MILES D, THOMSEN L, BALKWILL F, THAVASU P and MONCADA S
European Journal of Clinical Investigation, Wiley vol. 24 (4), 287-290.
01-04-1994
Expression of tumour necrosis factor (TNFα) and its receptors in benign and malignant breast tissueMiles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD and Balkwwill FR
International Journal of Cancer, Wiley vol. 56 (6), 777-782.
15-03-1994
Cytokine therapy of cancer. The importance of knowing the context.Balkwill FR
European Cytokine Network vol. 5 (4), 379-385.
01-01-1994
Oncogene transgenic mice as therapeutic models in cancer researchThomas H and Balkwill FR
European Journal of Cancer, Elsevier vol. 30 (4), 533-537.
01-01-1994
1993
Phase I Study of Bryostatin 1: Assessment of Interleukin 6 and Tumor Necrosis Factor α Induction In VivoPhilip PA, Rea D, Thavasu P, Carmichael J, Stuart NSA, Rockett H, Talbot DC, Ganesan T, Pettit GR, Balkwill F and Harris AL
Journal of The National Cancer Institute, Oxford University Press (Oup) vol. 85 (22), 1812-1818.
17-11-1993
Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion.Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A and Balkwill F
Cancer Research vol. 53 (22), 5365-5369.
15-11-1993
Activity of type IV collagenases in benign and malignant breast diseaseDavies B, Miles D, Happerfield L, Naylor M, Bobrow L, Rubens R and Balkwill F
British Journal of Cancer, Springer Nature vol. 67 (5), 1126-1131.
01-05-1993
A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts.Davies B, Brown PD, East N, Crimmin MJ and Balkwill FR
Cancer Research vol. 53 (9), 2087-2091.
01-05-1993
Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression.Naylor MS, Stamp GW, Foulkes WD, Eccles D and Balkwill FR
Journal of Clinical Investigation, American Society For Clinical Investigation vol. 91 (5), 2194-2206.
01-05-1993
The cytokine wall chartBurke F, Naylor MS, Davies B and Balkwill F
Trends in Immunology, Elsevier vol. 14 (4)
01-04-1993
Fusion potential for vaccinesTaylor-Papadimitriou J and Balkwill F
Nature, Springer Nature vol. 362 (6422), 695-695.
01-04-1993
Temporal sequence and cellular origin of interleukin-2 stimulated cytokine gene expressionSaraya K and Balkwill F
British Journal of Cancer, Springer Nature vol. 67 (3), 514-521.
01-03-1993
The cytokine wall chartBurke F, Stuart Naylor M, Davies B and Balkwill F
Immunology Today vol. 14 (4)
01-01-1993
The effect of cytokines on cultured mononuclear cells from patients with B cell chronic lymphocytic leukemiaBurke F, Griffin D, Elwood N, Davis C, Stamp G, Rohatiner A, Lister TA and Balkwill F
Hematological Oncology, Wiley vol. 11 (1), 23-33.
01-01-1993
1992
Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2Miles D, Aderka D, Engelmann H, Wallach D and Balkwill F
British Journal of Cancer, Springer Nature vol. 66 (6), 1195-1199.
01-12-1992
Measuring cytokine levels in blood Importance of anticoagulants, processing, and storage conditionsThavasu PW, Longhurst S, Joel SP, Slevin ML and Balkwill FR
Journal of Immunological Methods, Elsevier vol. 153 (1-2), 115-124.
01-08-1992
Beta actin expression and organization of actin filaments in colorectal neoplasia.Naylor MS, Stamp GW and Balkwill FR
Epithelial Cell Biology vol. 1 (3), 99-104.
01-07-1992
Effects of intraperitoneal recombinant interleukin-1 β in intraperitoneal human ovarian cancer xenograft models: comparison with the effects of tumour necrosis factorMalik ST, East N, Boraschi D and Balkwill F
British Journal of Cancer, Springer Nature vol. 65 (5), 661-666.
01-05-1992
Tumour necrosis factor and cancerBalkwill FR
Cytokine & Growth Factor Reviews, Elsevier vol. 4 (2), 121-137.
01-01-1992
Antiproliferative and antitumor activity of TNF in vitro and in vivo.Malik ST and Balkwill FR
Immunology Series vol. 56, 239-268.
01-01-1992
1991
Antitumor activity of gamma-interferon in ascitic and solid tumor models of human ovarian cancer.Malik ST, Knowles RG, East N, Lando D, Stamp G and Balkwill FR
Cancer Research vol. 51 (24), 6643-6649.
15-12-1991
Effects of interferons and other cytokines on tumors in animals: A reviewThomas H and Balkwill FR
Pharmacology & Therapeutics, Elsevier vol. 52 (3), 307-330.
01-12-1991
Toxicity and reconstitution of recombinant interleukin-2 with albuminMiles DW, Longhurst SJ, Harper PG and Balkwill FR
The Lancet, Elsevier vol. 338 (8780)
01-12-1991
Epithelial ovarian cancer: a cytokine propelled disease?Malik S and Balkwill F
British Journal of Cancer, Springer Nature vol. 64 (4), 617-620.
01-10-1991
Enhancement of metastatic potential by gamma-interferon.Kelly SA, Gschmeissner S, East N and Balkwill FR
Cancer Research vol. 51 (15), 4020-4027.
01-08-1991
Differential effects of recombinant interferon α on constitutive and inducible cytochrome P450 isozymes in mouse liverStanley LA, Adams DJ, Balkwill FR, Griffin D and Wolf CR
Biochemical Pharmacology, Elsevier vol. 42 (2), 311-320.
01-07-1991
Human small‐cell lung‐cancer cells are cytokine‐resistant but NK/LAK‐sensitiveLagadec PF, Saraya KA and Balkwill FR
International Journal of Cancer, Wiley vol. 48 (2), 311-317.
10-05-1991
Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSFMalik S, Martin D, Hart I and Balkwill F
British Journal of Cancer, Springer Nature vol. 63 (3), 399-403.
01-03-1991
1990
Investigation of cytokine gene expression in human colorectal cancer.Naylor MS, Stamp GW and Balkwill FR
Cancer Research vol. 50 (14), 4436-4440.
15-07-1990
Reconstitution of interleukin 2 with albumin for infusionMiles D, Bird C, Wadhwa M, Summerhayes M, Balkwill F, Thorpe R and Rubens R
The Lancet, Elsevier vol. 335 (8705), 1602-1603.
01-06-1990
In situ detection of tumour necrosis factor in human ovarian cancer specimensNaylor MS, Malik STA, Stamp GWH, Jobling T and Balkwill FR
European Journal of Cancer, Elsevier vol. 26 (10), 1027-1030.
01-01-1990
Cells secreting tumour necrosis factor show enhanced metastasis in nude miceMalik STA, Naylor MS, East N, Oliff A and Balkwill FR
European Journal of Cancer, Elsevier vol. 26 (10), 1031-1034.
01-01-1990
Tumour necrosis factor as an anticancer agentBalkwill FR, Naylor MS and Malik S
European Journal of Cancer, Elsevier vol. 26 (5), 641-644.
01-01-1990
The complex effects of recombinant tumour necrosis factor-alpha (rhTNF-alpha) in human ovarian cancer xenograft models.Malik ST, Griffin DB, Naylor MS, Fiers W, Oliff A and Balkwill FR
Progress in Clinical and Biological Research vol. 349, 393-403.
01-01-1990
1989
Paradoxical effects of tumour necrosis factor in experimental ovarian cancerMalik STA, Griffin DB, Fiers W and Balkwill FR
International Journal of Cancer, Wiley vol. 44 (5), 918-925.
15-11-1989
Interferons alpha and gamma differ in their ability to cause tumour stasis and regression in vivoBalkwill FR, Griffin DB and Lee AE
European Journal of Cancer, Elsevier vol. 25 (10), 1481-1486.
01-10-1989
The cytokine networkBalkwill FR and Burke F
Trends in Immunology, Elsevier vol. 10 (9), 299-304.
01-09-1989
Effect of steroid hormones on human colorectal adenocarcinoma xenografts, of known steroid-receptor status, in nude miceStebbings WSL, Vinson GP, Farthing MJG, Balkwill F and Wood RFM
Journal of Cancer Research and Clinical Oncology, Springer Nature vol. 115 (5), 439-444.
01-09-1989
Action of recombinant alpha interferon against experimental and spontaneous metastases in a murine modelRamani P and Balkwill FR
International Journal of Cancer, Wiley vol. 43 (1), 140-146.
15-01-1989
Tumour necrosis factorBalkwill FR
British Medical Bulletin, Oxford University Press (Oup) vol. 45 (2), 389-400.
01-01-1989
Future prospects and problems.Fiers W and Balkwill FR
Cancer Surveys vol. 8 (4), 921-927.
01-01-1989
The relevance of animal tumour models to the preclinical screening of cytokines.Kelly SA, Malik ST and Balkwill FR
Cancer Surveys vol. 8 (4), 741-754.
01-01-1989
1988
Cytokines — soluble factors in immune responsesBalkwill F
Current Opinion in Immunology, Elsevier vol. 1 (2), 241-249.
01-12-1988
Human interferons inhibit experimental metastases of a human melanoma cell line in nude miceRamani P and Balkwill F
British Journal of Cancer, Springer Nature vol. 58 (3), 350-354.
01-09-1988
An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancerFentiman IS, Balkwill FR, Thomas BS, Russell MJ, Todd I and Bottazzo GF
European Journal of Cancer, Elsevier vol. 24 (8), 1299-1303.
01-08-1988
The anti-cancer activity of tumour necrosis factor.Malik S and Balkwill F
Research in Immunology vol. 139 (3), 285-288.
01-01-1988
1987
Enhanced metastases of a mouse carcinoma after in vitro treatment with murine interferon gammaRamani P and Balkwill FR
International Journal of Cancer, Wiley vol. 40 (6), 830-834.
15-12-1987
EVIDENCE FOR TUMOUR NECROSIS FACTOR/CACHECTIN PRODUCTION IN CANCERBalkwill F, Burke F, Talbot D, Tavernier J, Osborne R, Naylor S, Durbin H and Fiers W
The Lancet, Elsevier vol. 330 (8570), 1229-1232.
01-11-1987
2′,5′-Oligoadenylate Synthetase and Interferon in Peripheral Blood after Rubella, Measles, or Mumps Live Virus VaccineTilles JG, Balkwill F and Davilla J
Experimental Biology and Medicine, Frontiers vol. 186 (1), 70-74.
01-10-1987
A trial of human alpha interferon as an adjuvant agent in breast cancer after loco-regional recurrence.Fentiman IS, Balkwill FR, Cuzick J, Hayward JL and Rubens RD
European Journal of Surgical Oncology vol. 13 (5), 425-428.
01-10-1987
Therapeutic potential of tumor necrosis factor-alpha and gamma-interferon in experimental human ovarian cancer.Balkwill FR, Ward BG, Moodie E and Fiers W
Cancer Research vol. 47 (18), 4755-4758.
15-09-1987
INTERFERONS IN CANCER THERAPY: A REAPPRAISALBalkwill FR and Smyth JF
The Lancet, Elsevier vol. 330 (8554), 317-319.
01-08-1987
Interferons in oncology: Current status and future directionsSmyth JF, Balkwill FR, Cavalli F, Kimchi A, Mattson K, Niederle NE and Spiegel RJ
European Journal of Cancer, Elsevier vol. 23 (6), 887-889.
01-06-1987
The effect of recombinant human tumour necrosis factor on growth and macromolecular synthesis of human epithelial cellsDealtry GB, Naylor MS, Fiers W and Balkwill FR
Experimental Cell Research, Elsevier vol. 170 (2), 428-438.
01-06-1987
Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice.Ward BG, Wallace K, Shepherd JH and Balkwill FR
Cancer Research vol. 47 (10), 2662-2667.
15-05-1987
Induction and suppression of glutathione transferases by interferon in the mouse.Adams DJ, Balkwill FR, Griffin DB, Hayes JD, Lewis AD and Wolf CR
Journal of Biological Chemistry, Elsevier vol. 262 (10), 4888-4892.
01-04-1987
DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon‐γDealtry GB, Naylor MS, Fiers W and Balkwill FR
European Journal of Immunology, Wiley vol. 17 (5), 689-693.
01-01-1987
Effects of Tumour Necrosis Factor on Human Tumour Xenografts in Nude MiceBalkwill FR, Ward BG and Fiers W
Novartis Foundation Symposia, Wiley vol. 131, 154-169.
01-01-1987
Interferon gamma regulates HLA-D expression on solid tumors in vivoBalkwill FR, Stevens MH, Griffin DB, Thomas JA and Bodmer JG
European Journal of Cancer, Elsevier vol. 23 (1), 101-106.
01-01-1987
1986
Enhancement by gamma-interferon of in vivo tumor radiolocalization by a monoclonal antibody against HLA-DR antigen.Rowlinson G, Balkwill F, Snook D, Hooker G and Epenetos AA
Cancer Research vol. 46 (12 Pt 1), 6413-6417.
01-12-1986
Augmentation of cytotoxicity of chemotherapy by human alpha-interferons in human non-small cell lung cancer xenografts.Carmichael J, Fergusson RJ, Wolf CR, Balkwill FR and Smyth JF
Cancer Research vol. 46 (10), 4916-4920.
01-10-1986
Effects of mouse interferon on human tumour xenografts in the nude mouse hostBalkwill FR and Proietti E
International Journal of Cancer, Wiley vol. 38 (3), 375-380.
15-09-1986
Interferons: from molecular biology to man. Part 3. Interferons and disease.Balkwill FR
Microbiological Sciences vol. 3 (9), 281-284.
01-09-1986
Interferons: from molecular biology to man. Part 2. Interferons and cell function.Balkwill FR
Microbiological Sciences vol. 3 (8), 229-233.
01-08-1986
Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons.Balkwill FR, Lee A, Aldam G, Moodie E, Thomas JA, Tavernier J and Fiers W
Cancer Research vol. 46 (8), 3990-3993.
01-08-1986
Interferons: from molecular biology to man. Part 1. Genetics and molecular biology of the interferon system.Balkwill FR
Microbiological Sciences vol. 3 (7), 212-215.
01-07-1986
The effect of interferon on experimental metastases in immunocompetent and immunodeficient miceRamani P, Hart IR and Balkwill FR
International Journal of Cancer, Wiley vol. 37 (4), 563-568.
15-04-1986
[85] Animal models for investigating antitumor effects of interferonBalkwill FR
Methods in Enzymology, Elsevier vol. 119, 649-657.
01-01-1986
1985
Antiviral and antiproliferative effects of interferons in quiescent fibroblasts are dissociableTaylor-Papadimitriou J, Balkwill F, Ebsworth N and Rozengurt E
Virology, Elsevier vol. 147 (2), 405-412.
01-12-1985
Differential action of six human interferons against two human carcinomas growing in nude miceBalkwill FR, Goldstein L and Stebbing N
International Journal of Cancer, Wiley vol. 35 (5), 613-617.
15-05-1985
PRIMARY HYPOTHYROIDISM ASSOCIATED WITH INTERFERON THERAPY OF BREAST CANCERFentiman IS, Thomas BS, Balkwill FR, Rubens RD and Hayward JL
The Lancet, Elsevier vol. 325 (8438)
01-05-1985
USE OF INTERFERON IN THE MANAGEMENT OF PATIENTS WITH SUBACUTE SCLEROSING PANENCEPHALITISBye A, Balkwill F, Brigden D and Wilson J
Developmental Medicine & Child Neurology, Wiley vol. 27 (2), 170-175.
01-04-1985
Central Nervous System Toxicity of InterferonRohatiner AZS, Prior P, Burton A, Balkwill F and Lister TA
Progress in Tumor Research, Karger Publishers vol. 29, 197-202.
01-01-1985
Recombinant DNA human interferon alpha 2 in advanced breast cancer: A phase 2 trialPadmanabhan N, Balkwill FR, Bodmer JG and Rubens RD
British Journal of Cancer, Springer Nature vol. 51 (1), 55-60.
01-01-1985
1984
Monoclonal antibodies that distinguish between subspecies of human interferon-alpha and that detect interferon oligomers.Shearer M, Taylor-Papadimitriou J, Griffin D and Balkwill F
The Journal of Immunology, The American Association of Immunologists vol. 133 (6), 3096-3101.
01-12-1984
Differential effects of pure human alpha and gamma interferons on fibroblast cell growth and the cell cycleBalkwill FR and Bokhon'ko AI
Experimental Cell Research, Elsevier vol. 155 (1), 190-197.
01-11-1984
Positive interactions between interferon and chemotherapy due to direct tumor action rather than effects on host drug-metabolizing enzymes.Balkwill FR, Mowshowitz S, Seilman SS, Moodie EM, Griffin DB, Fantes KH and Wolf CR
Cancer Research vol. 44 (11), 5249-5255.
01-11-1984
Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system.Balkwill FR and Moodie EM
Cancer Research vol. 44 (3), 904-908.
01-03-1984
Preclinical and clinical studies of interferons and interferon inducers in breast cancerBorden EC and Balkwill FR
Cancer, Wiley vol. 53 (S3), 783-789.
01-02-1984
Preclinical and clinical studies of interferons and interferon inducers in breast cancerBorden EC and Balkwill FR
Cancer vol. 53 (3 S), 783-789.
01-01-1984
1983
Experience with human lymphoblastoid interferon in acute myelogenous leukaemia (AML)Rohatiner AZS, Balkwill FR, Malpas JS and Lister TA
Cancer Chemotherapy and Pharmacology, Springer Nature vol. 11 (1), 56-58.
01-08-1983
Central nervous system toxicity of interferonRohatiner AZ, Prior PF, Burton AC, Smith AT, Balkwill FR and Lister TA
British Journal of Cancer, Springer Nature vol. 47 (3), 419-422.
01-03-1983
Immune human lymphocytes produce an acid-labile α-interferonBalkwill , Griffin D, Band H and Beverley P
Journal of Experimental Medicine, Rockefeller University Press vol. 157 (3), 1059-1063.
01-03-1983
Interferon in Acute Myelogenous Leukaemia: A Preliminary ReportRohatiner AZS, Balkwill F and Lister TA
, Springer Nature vol. 28, 56-58.
01-01-1983
A Paralytic Disease in Nude Mice Associated with Polyoma Virus InfectionMcCance DJ, Sebesteny A, Griffin BE, Balkwill F, Tilly R and Gregson NA
Journal of General Virology, Microbiology Society vol. 64 (1), 57-67.
01-01-1983
An Animal Model System for Investigating the AntiTumor Effects of Human InterferonBALKWILL FR, MOODIE EM, FREEDMAN V, LANE EB and FANTES KH
Journal of Interferon & Cytokine Research, Mary Ann Liebert vol. 3 (3), 319-326.
01-01-1983
1982
Implications for clinical application of new developments in interferon researchTaylor-Papadimitriou J and Balkwill FR
Biochimica Et Biophysica Acta, Elsevier vol. 695 (1), 49-67.
01-09-1982
Human interferon inhibits the growth of established human breast tumours in the nude mouseBalkwill FR, Moodie EM, Freedman V and Fantes KH
International Journal of Cancer, Wiley vol. 30 (2), 231-235.
15-08-1982
The ppp(A2′p)nA and Protein Kinase Systems in Wild‐Type and Interferon‐Resistant Daudi CellsSILVERMAN RH, WATLING D, BALKWILL FR, TROWSDALE J and KERR IM
The Febs Journal, Wiley vol. 126 (2), 333-341.
01-08-1982
Effects of HuIFN-α2 and HuIFN-α (Namalwa) on Breast Cancer Cells Grown in Culture and as Xenografts in the Nude MouseTAYLOR-PAPADIMITRIOU J, SHEARER M, BALKWILL FR and FANTES KH
Journal of Interferon & Cytokine Research, Mary Ann Liebert vol. 2 (4), 479-491.
01-01-1982
A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusionRohatiner AZS, Balkwill FR, Griffin DB, Malpas JS and Lister TA
Cancer Chemotherapy and Pharmacology, Springer Nature vol. 9 (2), 97-102.
01-01-1982
1981
Extracts from the last century. Mechanical dentistry--on regulation cases by F.H. BalkwillBalkwill FH
British Dental Journal, Springer Nature vol. 151 (1), 19-19.
01-07-1981
Species restriction in cytostatic activity of human and murine monocytes and macrophages.Hogg N and Balkwill FR
Immunology vol. 43 (1), 197-204.
01-05-1981
A Phase I Study of Human Lymphoblastoid Interferon in Patients with Hematological MalignanciesRohatiner A, Balkwill F, Malpas JS and Lister TA
, Springer Nature vol. 26, 63-67.
01-01-1981
A phase I study of intravenous human lymphoblastoid interferon (HLBI)Rohatiner AZS, Balkwill F, Malpas JS and Lister TA
Proceedings of The American Association For Cancer Research vol. Vol. 22
01-01-1981
1980
Demyelination and wasting associated with polyomavirus infection in nude (nu/nu) miceSebesteny A, Tilly R, Balkwill F and Trevan D
Laboratory Animals, Sage Publications vol. 14 (4), 337-345.
01-10-1980
HUMAN LYMPHOBLASTOID INTERFERON CAN INHIBIT THE GROWTH OF HUMAN BREAST CANCER XENOGRAFTS IN ATHYMIC [NUDE] MICEBalkwill F, Taylor‐Papadimitriou J, Fantes KH and Sebesteny A
Annals of The New York Academy of Sciences, Wiley vol. 350 (1), 591-592.
01-10-1980
Human lymphoblastoid interferon can inhibit the growth of human breast cancer xenografts in athymic (nude) miceBalkwill F, Taylor-Papadimitriou J, Fantes KH and Sebesteny A
European Journal of Cancer, Elsevier vol. 16 (4), 569-573.
01-04-1980
1979
REMISSION IN ACUTE MYELOBLASTIC LEUKÆMIABalkwill FR and Oliver RTD
The Lancet, Elsevier vol. 314 (8149), 961-962.
01-11-1979
Characterization of human breast milk macrophages cytostatic for human cell lines.Balkwill FR and Hogg N
The Journal of Immunology, The American Association of Immunologists vol. 123 (4), 1451-1456.
01-10-1979
Interferons as cell-regulatory moleculesBalkwill FR
Cancer Immunology, Immunotherapy, Springer Nature vol. 7 (1), 7-14.
01-10-1979
1978
Inhibition by lymphoblastoid interferon of growth of cells derived from the human breastBalkwill F, Watling D and Taylor‐Papadimitriou J
International Journal of Cancer, Wiley vol. 22 (3), 258-265.
15-09-1978
Interferon affects both G1 and S+G2 in cells stimulated from quiescence to growthBALKWILL F and TAYLOR-PAPADIMITRIOU J
Nature, Springer Nature vol. 274 (5673), 798-800.
01-08-1978
1977
Growth inhibitory effects of interferon on normal and malignant human haemopoietic cellsBalkwill FR and Oliver RTD
International Journal of Cancer, Wiley vol. 20 (4), 500-505.
15-10-1977
Neoplastic macrophages grown from human leukaemic monocytesBalkwill FR, Franks CR, Oliver RTD and Spector WG
The Journal of Pathology, Wiley vol. 122 (1), 13-26.
01-05-1977
Growth of acute myeloid leukaemia as discrete subcutaneous tumours in immune-deprived miceFranks CR, Bishop D, Balkwill FR, Oliver RT and Spector WG
British Journal of Cancer, Springer Nature vol. 35 (5), 697-700.
01-05-1977
1976
Diagnostic and prognostic significance of peripheral blood cultural characteristics in adult acute leukaemiaBalkwill FR and Oliver RT
British Journal of Cancer, Springer Nature vol. 33 (4), 400-410.
01-04-1976
Morphological characterisation of adult acute leukaemia in short-term liquid culture.Balkwill FR and Oliver RT
(56), 87-90.
01-01-1976
1974
Factors influencing microculture of leukaemia cellsBALKWILL F, PINDAR A and CROWTHER D
Nature, Springer Nature vol. 251 (5477), 741-742.
01-10-1974
Grants
Grants of specific relevance to Predictive in vitro Models
Evaluation of the cytotoxic function of the AZ CAR-T cell products by employing human in vitro 3 D multicellar models of high grade serous ovarian cancerBeatrice Malacrida and Fran Balkwill
£119,779
12-09-2024 - 11-09-2025
REMODEL - ERC AdG 2021 Frances BalkwillFran Balkwill
£2,154,257 EPSRC - EU Scheme
01-10-2022 - 30-09-2027
Studying immune repertoire as an indicator for response to immunotherapy treatment in High-grade serous ovarian cancerSamar Mohamed Ibrahim Elorbany and Fran Balkwill
£24,208 CR-UK Cancer Research UK
15-02-2024 - 14-02-2025
Targeting immune cells to improve response the chemotherapy in high-grade serous ovarian cancerSamar Mohamed Ibrahim Elorbany and Fran Balkwill
£52,374 Barts and the London Charity
01-04-2023 - 31-03-2024
CRUK City of London Centre 2020 Consumables AwardFran Balkwill
£15,000 UCL University College London
03-12-2020 - 31-03-2021
CHILL COGNITION new versionChristopher Griffiths and Fran Balkwill
£302,743 Barts and the London Charity
01-09-2020 - 01-09-2024
Interplay between ovarian cancer stem cells and the tumour microenvironmentFran Balkwill
£230,324 Ovarian Cancer Research Alliance (USA)
01-01-2020 - 31-12-2023
Immunotheraphy and clear cell ovarian cancerFran Balkwill
£290,799 MRC Medical Research Council
01-01-2019 - 30-06-2022
The effect of chemotherapy on Macrophage subpopulations in high-grade ovarian serous carcinomaFran Balkwill
£20,000 Wellbeing of Women
03-12-2018 - 30-11-2020
Targeting the innate immune system in high grade serous ovarian cancerFran Balkwill
£1,924,190 CR-UK Cancer Research UK
01-10-2018 - 31-10-2024
Exploring novel immunotherapy combinations for the treatment of lung cancer- also look at Project 380880Maria Castellano Sanchez and Fran Balkwill
£45,000 ACERTA
26-03-2018 - 15-03-2021
Advanced solid tissue models of T cell migration and activityFran Balkwill
£100,028 BBSRC Biotechnology and Biological Sciences Research Council
02-10-2017 - 25-03-2022
Advanced solid tissue models of T-cell migration and activityFran Balkwill
£32,000 GSK GlaxoSmithKline UK Ltd
01-10-2017 - 25-03-2022
Investigating the tumour extracellular matrix in the inhibition of anti-tumour imunityOliver Pearce and Fran Balkwill
£113,891 UCB Pharma SPRL
01-10-2017 - 28-02-2021
Targeting the peritoneal tumour microenvironment of high grade serous ovarian cancer CIFG1C9RFran Balkwill
£1,652,914 CR-UK Cancer Research UK
01-08-2017 - 31-03-2019
The effects of neo-adjuvant chemotherapy on myleoid cells in high-grade serous ovarian cancer metastases CIFG1E4RFran Balkwill
£313,427 Wellcome Trust
01-05-2016 - 30-04-2019